Pacific Biosciences

Valuation Analysis

About the Company

Pacific Biosciences en bref

Pacific Biosciences (PACB) is currently trading at 1,21 € with a market capitalization of 377 M €. The 52-week range spans from 0,95 € to 2,37 €; the current price is 48.7% below the yearly high. Year-over-year revenue growth stands at +0.1%.

💰 Dividende

Pacific Biosciences currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Pacific Biosciences (PACB) au consensus : Acheter. L'objectif de cours moyen est de 2,13 €, soit un potentiel de +75.6% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 1,30 € à 2,60 €.

Pacific Biosciences : la thèse d'investissement en détail

Pacific Biosciences (PACB) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 75.6% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 0.1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 29855.79% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 75.6% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (17.11%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Pacific Biosciences?

Compare top-rated brokers — low fees, trusted providers, fully regulated.